Given that Gal-1 is highly expressed in the microenvironment within the eyes of patients suffering from retinopathies [129, 130], its inhibition may offer a therapeutic approach for preventing the visual impairment caused by retinopathies [129–132]. Here, LGALS1 is linked to retinal disorder.